ELMERICE TRAKS, M.D.; DONALD B. HACKEL, M.D.; SALVATORE M. SANCETTA, M.D., F.A.C.P.
The continued pharmacologic search for drugs capable of producing a positive increase in the coronary blood of man is an important phase in the management of patients with coronary artery disease. It is a distressing fact that many substances which pharmacologically appear to be promising later fail to fulfill this promise in the course of direct clinical trial. The clinical use of such "vasodilator" substances is often predicated upon the physiologic observation that they produce an increased coronary blood flow in animal preparations, without considering the possibility that the increase in flow may represent solely a heightened myocardial demand induced
TRAKS E, HACKEL DB, SANCETTA SM. EFFECTS OF A NEW "CORONARY VASODILATOR" ON THE GENERAL AND CORONARY HEMODYNAMICS AND MYOCARDIAL METABOLISM OF MAN*†. Ann Intern Med. 1959;51:31–38. doi: https://doi.org/10.7326/0003-4819-51-1-31
Download citation file:
Published: Ann Intern Med. 1959;51(1):31-38.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use